Traditional Chinese Medicine Injections Combined With Oseltamivir for Influenza: Systematic Review and Network Meta-Analysis
Open Access
- 22 July 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 848770
- https://doi.org/10.3389/fphar.2022.848770
Abstract
Background: As a cause of respiratory tract infections in humans, influenza remains high morbidity and mortality, with associated significant healthcare burden and increased financial burden. Traditional Chinese medicine injections (TCMIs) combined with oseltamivir (TCMIs+oseltamivir) are the representative therapeutic strategies for influenza, which is compliant with clinical applications in China. To describe the comparative efficacy and safety of TCMIs+oseltamivir in patients with influenza, based on the current evidence. Methods: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, VIP information resource integration service platform databases, and Chinese biomedical literature service system, to find randomized controlled trials that TCMIs+oseltamivir for influenza, from inception until October 2021, without language restriction. Two investigators independently screened eligibility criteria, extracted data and appraised risk of bias with same criteria. We conducted network meta-analysis by Bayesian random method for each outcome and performed the sensitivity analysis, meta-regressions, and Egger’s and Begg’s tests for reliability and robustness of our results. Results: Thirty-one trials including 2893 participants proved eligible and reported on four TCMIs+oseltamivir versus oseltamivir. Network meta-analysis showed Xiyanping (XYP) +oseltamivir (OR = 5.9, 95% CrI: 3.1 to 11; SUCRA = 0.82) in response rate, Yanhuning (YHN) +oseltamivir (MD = -1.7, 95% CrI: -2.5 to -0.88; SUCRA = 0.89) in fever disappearance time, Tanreqing (TRQ) +oseltamivir (MD = -1.9, 95% CrI: -2.8 to -1; SUCRA = 0.97) in cough disappearance time, more efficacious than oseltamivir alone with the best SUCRA, respectively. Based on the combined SUCRA value for primary outcomes, TRQ+oseltamivir probably better in cough disappearance time, and XYP+oseltamivir and YHN+oseltamivir may better in fever disappearance time than others. No significant difference in safety between the treatments. Conclusion: In patients with influenza, TCMIs+oseltamivir may reduce cough and fever disappearance time, with no significant differences in harms. However, the safety remains uncertain, TCMI treatments for influenza should be considered with caution. More high-quality studies examining the efficacy and safety of TCMIs are needed.Funding Information
- National Natural Science Foundation of China
This publication has 38 references indexed in Scilit:
- The burden of influenza in England by age and clinical risk group: A statistical analysis to inform vaccine policyJournal of Infection, 2014
- Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant dataThe Lancet Respiratory Medicine, 2014
- Global Mortality Estimates for the 2009 Influenza Pandemic from the GLaMOR Project: A Modeling StudyPLoS Medicine, 2013
- Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United StatesAntiviral Research, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tablesJournal of Clinical Epidemiology, 2011
- Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is lifeJournal of Antimicrobial Chemotherapy, 2011
- Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populationsJournal of Antimicrobial Chemotherapy, 2010
- Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold?Clinical Infectious Diseases, 2009
- Influenza-Associated Hospitalizations in the United StatesJAMA, 2004